Sánchez MCM

Language: Spanish
References: 6
Page: 91-91
PDF size: 65.97 Kb.

REFERENCES

1. Steinmaurer A, Wimmer I, Berger T et al. Bruton's tyrosine kinase inhibition in the treatment of preclinical models and multiple sclerosis. Curr Pharm Des. 2022; 28 (6): 437-444.

2. ClinicalTrials.gov [Internet]. Bethesda (MD): National library of medicine (US). Study to assess the efficacy and safety of ublituximab in participants with relapsing forms of multiple sclerosis (RMS) (ULTIMATE 1). ClinicalTrials.gov Identifier: NCT03277261. Last Update Posted: December 6, 2021.

3. Fox RJ, Coffey CS, Conwit R et al. NN102/SPRINT-MS trial investigators. phase 2 trial of ibudilast in progressive multiple sclerosis. N Engl J Med. 2018; 379 (9): 846-855.

4. Hartung HP, Derfuss T, Cree BA et al. Efficacy and safety of temelimab in multiple sclerosis: results of a randomized phase 2b and extension study. Mult Scler. 2022; 28 (3): 429-440.

5. A study to assess the safety and efficacy of elezanumab when added to standard of care in progressive forms of multiple sclerosis. ClinicalTrials.gov Identifier: NCT03737812. Last Update Posted: December 20, 2021.

6. Efficacy and safety of BIIB033 (Opicinumab) as an add-on therapy to disease-modifying therapies (DMTs) in relapsing multiple sclerosis (MS) (AFFINITY). ClinicalTrials.gov Identifier: NCT03222973. Last Update Posted: April 28, 2022.